spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
import
viral
structur
protein
base
bioinformat
analysi
antigen
peptid
deriv
protein
sequenc
select
synthes
antigen
immunoreact
peptid
test
vivo
vitro
four
peptid
contain
b
cell
epitop
protein
identifi
peptid
confirm
vivo
potenti
serolog
diagnosi
use
syncytia
format
model
test
neutral
abil
peptid
correspond
antibodi
interest
find
peptid
inhibit
syncytia
format
suggest
span
region
may
provid
good
target
antisarscov
drug
design
data
suggest
identifi
peptid
deriv
protein
sarscov
use
sar
treatment
diagnosi
sever
acut
respiratori
syndrom
sar
seriou
epidem
infecti
diseas
occur
novemb
septemb
reappear
part
china
devast
diseas
rel
high
mortal
sarsassoci
coronaviru
name
sarscov
pathogen
disast
new
kind
coronaviru
envelop
positivestrand
rna
rna
viru
singlestrand
genom
contain
four
structur
protein
spike
protein
membran
protein
small
envelop
protein
nucleocapsid
n
protein
sarscov
spread
quickli
china
mani
countri
sinc
effect
method
far
prevent
treat
diseas
accur
diagnost
method
effect
clinic
antivir
drug
vaccin
urgent
need
protein
sarscov
good
candid
diseas
diagnosi
vaccin
design
protein
gi
consist
amino
acid
sever
glycosyl
site
believ
protein
two
domain
play
import
role
viru
bind
virusreceptor
mediat
fusion
viral
particl
target
cell
accord
current
work
confirm
protein
cleav
two
part
predict
protein
yield
two
fragment
span
residu
peptid
sequenc
residu
length
select
protein
peptid
locat
part
peptid
locat
base
seri
bioinformat
analysi
peptid
use
immun
rabbit
specif
antisera
induc
peptid
analyz
western
blot
recombin
express
protein
well
lysat
sarscov
infect
vero
cell
sar
sera
use
confirm
specif
immunoreact
select
peptid
syncytia
format
model
use
evalu
neutral
abil
peptid
correspond
antibodi
ab
data
demonstr
peptid
show
high
antigen
immunoreact
antisera
peptid
immun
rabbit
show
good
specif
high
affin
protein
confirm
peptid
best
candid
usag
sar
serolog
diagnosi
optim
peptid
deriv
reveal
specif
respons
sar
specif
igg
abbrevi
sarscov
sever
acut
respiratori
syndromeassoci
coronaviru
ab
antibodi
sar
sera
gave
posit
rate
test
sar
patient
neutral
experi
use
syncytia
format
model
show
peptid
markedli
inhibit
syncytia
format
indic
correspond
region
span
sequenc
within
protein
may
new
target
effici
sar
drug
develop
analyz
sar
spike
protein
gi
softwar
dnastar
peptid
select
whole
sequenc
protein
base
indic
antigen
hydrophil
surfac
probabl
flexibl
region
peptid
synthes
use
convent
solidphas
chemic
methodolog
purifi
gl
biochem
shanghai
ltd
bovin
serum
albumin
bsa
sigma
serv
carrier
protein
conjug
peptid
new
zealand
white
rabbit
shanghai
laboratori
anim
center
chines
academi
scienc
immun
subcutan
back
rabbit
lg
differ
bsaconjug
peptid
emulsifi
vv
complet
adjuv
cfa
amount
peptid
dissolv
incomplet
adjuv
ifa
use
boost
immun
rabbit
day
follow
immun
antisera
collect
day
follow
first
immun
recombin
intact
protein
fragment
express
escherichia
coli
purifi
model
electroelut
biorad
subject
sdspage
analysi
vero
cell
infect
sarscov
h
collect
previous
describ
infect
cell
lyse
solut
contain
mm
tri
ph
nonid
min
viru
lysat
centrifug
rpm
min
supernat
collect
boil
min
experi
use
viru
carri
biosafeti
level
laboratori
express
whole
length
protein
fragment
well
nativ
protein
extract
lysat
sarscov
infect
vero
cell
use
detect
bind
activ
peptideinduc
antisera
bind
ab
detect
second
ab
hrpconjug
goat
antirabbit
igg
ecldetect
reagent
amersham
pharmacia
biotech
use
develop
film
sera
sar
patient
sera
healthi
individu
use
experi
use
sera
carri
biosafeti
level
laboratori
confirm
sar
sera
igg
posit
analyz
elisa
use
whole
viru
lysat
reactiv
peptid
sar
sera
also
measur
elisa
plate
coat
bsapeptid
conjug
lgml
llwell
coat
buffer
ph
overnight
afterward
well
wash
pb
block
bsa
h
sera
purifi
igg
sar
sera
ad
first
ab
sera
dilut
purifi
igg
dilut
plate
store
min
wash
pb
hrpcoupl
goat
antihuman
igg
biorad
ad
od
valu
measur
micropl
autoread
biotek
nm
syncytia
format
use
mimic
sarscov
infect
procedur
studi
modifi
assay
introduc
luciferas
assay
detect
system
fig
b
cell
fusiondepend
report
gene
luciferas
activ
assay
adapt
studi
spike
proteinmedi
membran
fusion
brief
effector
cell
gener
cotransfect
cell
monolay
mm
dish
plasmid
puhd
target
cell
contain
luciferas
report
gene
gener
cotransfect
cell
puhd
twentyfour
hour
transfect
effector
cell
target
cell
trypsin
resuspend
fb
two
kind
cell
suspens
mix
cell
number
repellet
antisera
peptid
antiserum
lm
peptid
ad
cell
suspens
mixtur
investig
inhibitori
capac
antiserum
peptid
incub
cell
suspens
h
replat
cultur
plate
h
final
media
remov
cell
lyse
passiv
lysi
buffer
promega
luciferas
intens
measur
luminomet
predict
cleavag
site
sarscov
spike
protein
contain
residu
locat
amino
acid
residu
fragment
repres
respect
peptid
design
accord
four
characterist
antigen
surfac
probabl
hydrophil
flexibl
region
peptid
deriv
fragment
peptid
fragment
fig
tabl
western
blot
order
test
antigen
synthet
peptid
immun
rabbit
coupl
bsa
antisera
high
titer
collect
day
follow
immun
bind
activ
specif
ab
determin
western
blot
e
coli
express
fragment
fragment
fulllength
protein
well
nativ
protein
isol
lysat
sarscov
infect
cell
data
demonstr
antisera
bound
fragment
also
show
weak
nonspecif
bind
activ
lysat
viru
fig
map
peptid
use
immun
spike
protein
predict
cleav
amino
acid
accord
bioinformat
analysi
fulllength
protein
fragment
express
e
coli
serv
target
protein
western
blot
b
eight
peptid
sequenc
select
fragment
two
peptid
sequenc
select
fragment
infect
cell
suggest
three
ab
poor
bind
specif
protein
sarscov
contrast
antisera
specif
bind
fragment
protein
express
e
coli
sarscov
infect
cell
lysat
suggest
ab
potenti
recogn
protein
sarscov
natur
form
fig
tabl
igg
purifi
sar
sera
studi
immunogen
peptid
deriv
protein
sarscov
vivo
proteinspecif
igg
purifi
sar
sera
mixtur
contain
igg
serv
templat
determin
reaction
peptid
ten
peptid
show
differ
immunoreact
purifi
igg
peptid
reveal
rel
higher
respons
peptid
fig
peptid
highest
immunoreact
may
contain
potenti
domin
b
cell
epitop
protein
sarscov
sinc
peptid
react
purifi
igg
sar
sera
ask
whether
peptid
could
use
antigen
sar
serolog
diagnosi
initi
address
possibl
reaction
sera
sar
patient
well
normal
individu
test
elisa
peptid
deriv
murin
cnrldlginlspdlaesprfi
serv
neg
control
tabl
sn
nativ
spike
protein
se
recombin
protein
express
e
coli
recombin
fragment
protein
express
e
coli
recombin
fragment
immunoreact
peptid
purifi
igg
sar
sera
serv
sprotein
specif
ab
bsa
use
neg
control
bind
activ
igg
peptid
deriv
protein
detect
elisa
purifi
human
igg
sar
patient
dilut
hrpcoupl
antihuman
igg
serv
second
ab
expect
good
posit
respons
sera
sar
patient
posit
sar
patient
howev
also
fals
posit
respons
sera
normal
individu
posit
case
wherea
control
peptid
show
neg
respons
sera
sar
patient
uninfect
normal
individu
tabl
like
short
peptid
amino
acid
residu
length
suffici
mimic
specif
b
cell
epitop
within
protein
addit
linear
b
cell
epitop
conform
structur
synthet
peptid
might
also
help
form
specif
bind
site
recogn
correspond
ab
vivo
assum
extend
peptid
longer
may
help
creat
specif
bind
site
peptid
extend
amino
acid
sequenc
psskrfqpf
note
mean
number
sera
sar
patient
healthi
peopl
p
number
posit
respons
reactiv
percentag
total
test
sera
fig
extend
peptid
show
higher
immunoreact
higher
specif
higher
affin
igg
purifi
sera
sar
patient
b
specif
peptid
sar
sera
compar
peptid
show
high
specif
affin
sar
sera
respons
sera
health
control
qqfgrdvsdftdsvrdpktse
refer
confirm
hypothesi
proteinspecif
igg
purifi
sera
sar
patient
bind
affin
igg
compar
elisa
expect
show
higher
affin
fig
result
support
hypothesi
confirm
whether
could
suitabl
diagnosi
sar
sera
obtain
diagnos
sar
patient
uninfect
normal
individu
bind
specif
sarsspecif
igg
measur
elisa
parallel
experi
sar
patient
test
posit
contrast
normal
healthi
individu
test
posit
fig
control
peptid
low
rate
bind
sera
patient
uninfect
peopl
like
amino
acid
length
peptid
might
creat
conform
structur
within
protein
recogn
proteinspecif
ab
vivo
protein
syncytia
format
model
wide
use
assay
detect
neutral
activ
ab
peptid
initi
make
sure
whether
syncytia
format
model
work
well
test
model
use
neutral
monoclon
ab
gener
lab
specif
protein
fragment
sarscov
neutral
activ
confirm
sarscov
infect
vero
cell
data
shown
data
demonstr
syncytia
format
inhibit
ab
fig
b
result
indic
model
suitabl
test
neutral
activ
ab
peptid
potenti
prevent
sar
infect
peptid
correspond
ab
evalu
model
interest
note
compar
control
antisera
antisera
minor
influenc
syncytia
format
antisera
fig
result
show
peptideinduc
polyclon
ab
unabl
inhibit
syncytia
format
suggest
test
ab
neutral
activ
antiserum
test
model
also
show
inhibit
data
shown
recent
mani
report
demonstr
peptid
good
candid
antiviru
drug
design
studi
also
test
peptidemedi
inhibit
use
model
obviou
peptid
could
significantli
inhibit
syncytia
format
fig
c
data
indic
region
span
peptid
sequenc
within
protein
might
repres
new
target
drug
develop
sarscov
spike
protein
essenti
structur
protein
life
span
import
function
sar
pathogenesi
play
import
role
viral
infect
also
potenti
drug
target
studi
probe
b
cell
epitop
protein
bioinformat
analysi
peptid
immun
vivo
explor
potenti
usag
diseas
diagnosi
treatment
fig
neutral
test
syncytia
format
model
six
antisera
good
reaction
protein
select
test
inhibit
ab
show
minor
inhibit
group
transduc
cell
syncytia
format
group
ab
use
test
result
complet
syncytia
format
group
antibodi
irrel
peptid
n
protein
sarscov
use
test
control
b
peptid
use
test
peptid
inhibit
syncytia
format
nearli
group
transduc
cell
syncytia
format
group
peptid
use
test
result
complet
syncytia
format
n
group
irrelev
peptid
n
protein
sarscov
use
test
control
inhibit
observ
c
peptid
select
test
data
demonstr
inhibit
remark
experi
repeat
sever
time
group
transduc
cell
syncytia
format
group
peptid
use
test
result
complet
syncytia
format
n
group
irrelev
peptid
use
test
inhibit
observ
although
peptid
show
high
antigen
index
ai
epitop
predict
score
accord
bioinformat
analysi
could
induc
strong
specif
immun
respons
data
suggest
ai
peptid
crucial
factor
fact
flexibl
region
hydrophil
surfac
probabl
also
import
factor
epitop
predict
order
test
bioinformat
analysi
result
seri
experi
perform
confirm
peptid
contain
relev
b
cell
epitop
within
protein
sarscov
nativ
protein
lysat
sarscov
infect
vero
cell
purifi
proteinspecif
igg
sar
patient
use
determin
antigen
immunoreact
data
demonstr
span
region
contain
good
b
cell
epitop
protein
potenti
applic
sar
diagnosi
unexpectedli
peptid
highli
antigen
cross
reactiv
sera
obtain
uninfect
normal
individu
sequenc
analysi
show
small
fragment
length
peptid
psskrfqpfqqfgrdvsdft
share
homolog
pathogen
human
tissu
antigen
one
report
demonstr
bootscan
recombin
analysi
spike
gene
reveal
high
nucleotid
ident
sar
viru
felin
infecti
periton
viru
throughout
gene
except
region
high
ident
avian
sequenc
indic
mammalianavian
mosaic
origin
hostdetermin
spike
protein
furthermor
experi
also
higher
cross
reactiv
sera
autoimmun
diseas
patient
sle
data
shown
result
suggest
peptid
homolog
either
normal
tissu
antigen
pathogen
contact
uninfect
normal
individu
lifetim
may
account
cross
reaction
attempt
optim
peptid
extend
length
ad
length
fragment
c
termin
obtain
peptid
specif
respons
rate
sar
patient
wherea
fals
posit
rate
uninfect
normal
individu
possibl
longer
form
conform
b
cell
epitop
specif
immunogen
shorter
data
confirm
hypothesi
current
mani
diagnost
method
sar
detect
real
time
rtpcr
elisa
viru
lysat
antigen
rtpcr
expens
appli
small
hospit
use
limit
clinic
set
due
difficulti
sampl
collect
low
level
accuraci
elisa
simpl
conveni
method
detect
sar
diagnost
kit
sarscov
avail
current
method
employ
lysat
viru
infect
vero
cell
antigen
could
use
sar
diagnosi
specif
adequ
safeti
concern
peptidebas
sar
elisa
test
advantag
test
much
cheaper
quicker
other
rtpcr
peptid
easi
safe
prepar
compar
whole
viru
lysat
conceiv
test
optim
use
one
peptid
often
improv
sensit
reliabl
diagnost
test
studi
demonstr
good
candid
usag
serolog
diagnosi
sar
synthet
peptid
also
use
develop
effici
sar
therapeut
drug
exampl
peptid
immun
gener
specif
ab
peptid
contain
neutral
epitop
inhibit
interact
viru
spike
protein
receptor
epitop
use
gener
effect
neutral
ab
vaccin
peptid
also
use
agent
inhibit
viru
infect
provid
spatial
block
protein
spike
syncytia
format
model
mimic
sarscov
infect
process
model
safe
use
laboratori
antisera
peptid
small
chemic
molecul
select
screen
neutral
abil
use
model
studi
success
identifi
four
b
cell
epitop
spike
protein
sarscov
show
neutral
activ
howev
peptid
test
neutral
abil
peptid
significantli
inhibit
syncytia
format
sequenc
compar
psskrfqpfqqfgrdvsdft
lsgia
show
special
characterist
two
peptid
span
sequenc
within
protein
differ
bind
site
fusion
motif
data
indic
two
region
protein
may
contain
crucial
new
drug
target
actual
mechan
inhibit
unclear
summari
bioinformat
analysi
peptid
immun
vivo
essenti
identifi
b
cell
epitop
given
antigen
sarscov
spike
protein
repres
immunogen
peptid
sequenc
protein
potenti
use
sar
diagnosi
neutral
abil
peptid
indic
respect
region
protein
may
contain
new
target
antisar
drug
develop
